J Korean Med Assoc.  2014 Jan;57(1):27-33. 10.5124/jkma.2014.57.1.27.

Diagnosis and treatment of multidrug-resistant tuberculosis

• Kang YA

• KMID: 2194831
• DOI: http://doi.org/10.5124/jkma.2014.57.1.27

Abstract

Multidrug-resistant tuberculosis (MDR-TB) is a great public health concern worldwide. MDR-TB denotes bacillary resistance to at least isoniazid and rifampicin. Extensively drug-resistant tuberculosis (XDR-TB) is MDR-TB with additional bacillary resistance to any fluoroquinolone and at least one second-line injectable drug. The treatment of MDR-TB requires prolonged administration of a toxic second line anti-tuberculosis drug and generally has poor outcomes. XDR-TB requires more complex treatment and has higher mortality. MDR- and XDR-TB arise because of inadequate or interrupted administration of first-line treatment and can be transmitted in the community. Thus, prevention of the emergence of resistance is the first principle in the management of MDR/XDR-TB. To prevent the emergence of drug resistance and transmission of MDR/XDR-TB, the adequate prescription of an anti-TB drug by a physician and good adherence of patients are essential. In addition, rapid diagnosis of drug resistance using molecular tests such as a line probe assay and Xpert MTB/RIF and the programmatic management of MDR/XDR-TB by designing an effective regimen using available drugs (a newer generation of fluoroquinolone, second-line injectable drugs, second-line oral drugs, and pyrazinamide) based on a guideline are an important strategy for controlling MDR/XDR TB. Despite the long duration of treatment, the treatment success rate of MDR-TB for patients who started treatment in 2009 has been 48% according to the World Health Organization. Thus, to improve the treatment outcomes of MDR/XDR-TB, new drug development is necessary.

Keyword

Resistance; Multidrug-resistant tuberculosis; Diagnosis; Therapeutics

MeSH Terms

Diagnosis*
Drug Resistance
Extensively Drug-Resistant Tuberculosis
Humans
Isoniazid
Mortality
Prescriptions
Public Health
Rifampin
Tuberculosis, Multidrug-Resistant*
World Health Organization
Isoniazid
Rifampin

Reference

1. World Health Organizaton. Global tuberculosis report 2012 [Internet]. Geneva: World Health Organizaton;2012. cited 2013 Dec 16. Available from: http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf.

2. Korea Centers for Disease Control and Prevention. Annual report on the notified tuberculosis patients in Korea, 2011. Cheonwon: Korea Centers for Disease Control and Prevention;2012.

3. Park YS, Hong SJ, Boo YK, Hwang ES, Kim HJ, Cho SH, Na KI, Cho EH, Shin SS. The national status of tuberculosis using nationwide medical records survey of patients with tuberculosis in Korea. Tuberc Respir Dis (Seoul). 2012; 73:48–55.

4. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009; 13:1320–1330.

5. STREPTOMYCIN treatment of pulmonary tuberculosis. Br Med J . 1948; 2:769–782.

6. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec. 2006; 81:430–432.

7. Mitchison DA. Drug resistance in tuberculosis. Eur Respir J. 2005; 25:376–379.

8. World Health Organizaton. Anti-tuberculosis drug resistance in the world. 3rd global report. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. Geneva: World Health Organization;2004.

9. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J. 2005; 25:564–569.

10. World Health Organizaton. Policy statement: molecular line probe assays for rapid screening of patients at risk of multi-drug-resistant tuberculosis. Geneva: World Health Organization;2008.

11. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010; 363:1005–1015.

12. World Health Organizaton. Policy statement: automated realtime nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Geneva: World Health Organization;2011.

13. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, Lee JK, Kim SJ. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis. 2007; 11:571–576.

14. Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis. 2004; 8:361–368.

15. Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, Choi YS, Kim K, Kim J, Shim YM, Koh WJ. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis. 2008; 47:496–502.

16. Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007; 45:1290–1295.

17. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, Kim EK, Lee KM, Lee SS, Park JS, Koh WJ, Lee CH, Kim JY, Shim TS. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med. 2008; 178:1075–1082.

18. Chiang CY, Schaaf HS. Management of drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2010; 14:672–682.

19. World Health Organizaton. Guidelines for the programmatic management of drug-resistant tuberulosis. Emergency update 2008. Geneva: World Health Organization;2008.

20. World Health Organizaton. Guidelines for the programmatic management of drug-resistant tuberulosis, 2011 update. Geneva: World Health Organization;2011.

21. Joint Committee for the Development of Korean Guideline for Tuberculosis. Korean Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. 1st ed. Cheongwon: Korea Centers for Disease Control and Prevention;2011.

22. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang CY, Cox H, D'Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ, Lancaster J, Lange C, de Lange WC, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, O'Riordan P, Pai M, Palmero D, Park SK, Pasvol G, Pena J, Perez-Guzman C, Quelapio MI, Poncede-Leon A, Riekstina V, Robert J, Royce S, Schaaf HS, Seung KJ, Shah L, Shim TS, Shin SS, Shiraishi Y, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Tabarsi P, Tupasi TE, van Altena R, Van der Walt M, Van der Werf TS, Vargas MH, Viiklepp P, Westenhouse J, Yew WW, Yim JJ. Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012; 9:e1001300.

23. Yew WW, Chan CK, Leung CC, Chau CH, Tam CM, Wong PC, Lee J. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest. 2003; 124:1476–1481.

24. Torun T, Gungor G, Ozmen I, Bolukbasi Y, Maden E, Bicakci B, Atac G, Sevim T, Tahaoglu K. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005; 9:1373–1377.

25. Kim HJ, Kang CH, Kim YT, Sung SW, Kim JH, Lee SM, Yoo CG, Lee CT, Kim YW, Han SK, Shim YS, Yim JJ. Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis. Eur Respir J. 2006; 28:576–580.

26. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010; 182:684–692.

27. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon HS, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee JK, Lee D, Kim CT, Dartois V, Park SK, Cho SN, Barry CE 3rd. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012; 367:1508–1518.

28. Mahajan R. Bedaquiline: first FDA-approved tuberculosis drug in 40 years. Int J Appl Basic Med Res. 2013; 3:1–2.

29. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012; 366:2151–2160.

30. Working Group on New TB Drugs. Drug pipeline [Internet]. [place unknown]: Working Group on New TB Drugs;cited 2013 Dec 16. Available from: http://www.newtbdrugs.org/pipeline.php.